Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
|Videos|March 2, 2019
Dr. Usmani Discusses Management of Early Relapse in Myeloma
Author(s)Saad Z. Usmani, MD, FACP
Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.
Advertisement
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, shares his advice for the management of early relapse in patients with multiple myeloma.
According to Usmani, one approach to this situation is not appropriate for all patients. Physicians should consider each regimen that could potentially be used for first relapse to decide which option is best for an individual patient. If there are 2 regimens with similar benefit, convenience for the patient should also be considered.
Advertisement
Related to this article
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
4
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
5